Management of hepatitis C in active drugs users: experience of an addiction care hepatology unit

被引:45
作者
Cournot, M
Glibert, A
Castel, F
Druart, F
Imani, K
Lauwers-Cances, V
Morin, T
机构
[1] Ctr Hosp Tarbes, Serv Hepatogastroenterol, F-65013 Tarbes, France
[2] INSERM, Dept Epidemiol, U558, F-31073 Toulouse, France
来源
GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE | 2004年 / 28卷 / 6-7期
关键词
D O I
10.1016/S0399-8320(04)95008-7
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective - Recent guidelines on the management of patients chronic hepatitis C virus (HCV) infection recommend the same anti-HCV therapy for active intravenous drug users and other patients, however some physicians are reluctant to treat active drug users. The aim of this study was to compare hepatitis C management practices and clinical outcome after treatment between active intravenous drug users and other patients. Methods - Four hundred and thirty-five naive HCV seropositive patients were recruited from 1990 to 2000 and followed up for a mean period of 2.5 years (SD 1 year). At the beginning of the study, 116 of the patients were active intravenous drug users. Social, clinical, biological and histological data were collected. The different steps of HCV management and responses to treatment were compared between active intravenous drug users and other patients. Results - There was no statistically significant difference in HCV management practices and compliance between active intravenous drug users and other patients: search for viral RNA (85% versus 67%), liver biopsy performed when indicated (82% versus 87%), initiation of anti-HCV treatment (33.6% versus 43.2%), loss to follow up during treatment (24% vs 16%). The rate of sustained viral response was not significantly different between active intravenous drug users and other patients (28% versus 21%). At multivariate analysis, factors independently associated with sustained viral response were female gender (OR = 5.6 [1.02-41.2]), genotype 3 (OR = 29.7 [1.4-61.7]), low viral load (OR = 33.3 [2,25-100]), low fibrosis score (OR = 1.4 [1.0-2.0]), elevated transaminase level (OR = 12.7 [0.9-97.2]), and bitherapy protocol (OR = 10 [1.18-85.3]). Conclusion - This study illustrates that active intravenous drug use does not affect either patient compliance with proposed management or viral response to treatment, but pluridisciplinary care should focus both on drug addiction and HCV infection.
引用
收藏
页码:533 / 539
页数:7
相关论文
共 18 条
[1]  
[Anonymous], 1999, J Hepatol, V31 Suppl 1, P3
[2]   Treatment of hepatitis C infection in injection drug users [J].
Backmund, M ;
Meyer, K ;
Von Zielonka, M ;
Eichenlaub, D .
HEPATOLOGY, 2001, 34 (01) :188-193
[3]   Treatment of chronic hepatitis C in active drug users [J].
Davis, GL ;
Rodrigue, JR .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :215-217
[4]   Hepatitis C in a French population-based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factors [J].
Dubois, F ;
Desenclos, JC ;
Mariotte, N ;
Goudeau, A ;
Drucker, J ;
Guignard, E ;
Buzelay, L ;
Allemand, H ;
Giordanella, JP ;
Tichet, J ;
Thevenas, C ;
Caces, E ;
Jacquelin, JM ;
Calvet, C ;
Lemauff, JM ;
Lepinay, P ;
Novak, M ;
Varsat, B ;
Rene, MN ;
Tilliet, JP ;
Raboutet, P ;
Leray, P ;
Janer, P ;
Pot, AM ;
Fournier, B ;
Maltesse, F ;
Campion, J ;
Lebrun, I ;
Henny, J ;
Aubry, C ;
Deforges, D ;
Radel, N ;
Seyve, D ;
Didelot, R ;
Pignol, AM ;
Gomez, P ;
EstopinaGil, AM ;
Lebas, AM .
HEPATOLOGY, 1997, 25 (06) :1490-1496
[5]   Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance [J].
Gerlach, JT ;
Diepolder, HM ;
Zachoval, R ;
Gruener, NH ;
Jung, MC ;
Ulsenheimer, A ;
Schraut, WW ;
Schirren, CA ;
Waechtler, M ;
Backmund, M ;
Pape, GR .
GASTROENTEROLOGY, 2003, 125 (01) :80-88
[6]  
Grando-Lemaire V, 2002, GASTROEN CLIN BIOL, V26, P1091
[7]  
Hagan H, 2000, MT SINAI J MED, V67, P423
[8]  
Hope VD, 2001, AM J PUBLIC HEALTH, V91, P38, DOI 10.2105/AJPH.91.1.38
[9]   Medical progress: Hepatitis C virus infection. [J].
Lauer, GM ;
Walker, BD .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) :41-52
[10]   What is the cost utility of screening for hepatitis C virus (HCV) in intravenous drug users? [J].
Leal, P ;
Stein, K ;
Rosenberg, W .
JOURNAL OF MEDICAL SCREENING, 1999, 6 (03) :124-131